IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo

Immunology Letters

Volumn 150, Issue 1-2, 2013, Pages 41-47

  Dyer, Kimberly D ^a   Percopo, Caroline M ^a   Rosenberg, Helene F ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Eosinophil; GM CSF; IL 33; IL 5

Indexed keywords

FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 33; INTERLEUKIN 5; NEUTRALIZING ANTIBODY; RANTES; STEM CELL FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EOSINOPHIL; EOSINOPHILIA; EX VIVO STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84874542228     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.12.002     Document Type: Article

References (43)

1. Takatsu K., Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol 2008, 20:288-294.
2. Roboz G.J., Rafii S. Interleukin-5 and the regulation of eosinophil production. Curr Opin Hematol 1999, 6:164-168.
3. Dyer K.D., Moser J.M., Czapiga M., Siegel S.J., Percopo C.M., Rosenberg H.F. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol 2008, 181:4004-4009.
4. Kurowska-Stolarska M., Hueber A., Stolarski B., McInnes I.B. Interleukin-33: a novel mediator with a role in distinct disease pathologies. J Intern Med 2011, 269:29-35.
5. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?. PLoS ONE 2008, 3:e3331.
6. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
7. Wood I.S., Wang B., Trayhurn P.I.L-33 a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 2009, 384:105-109.
8. Kouzaki H., Iijima K., Kobayashi T., O'Grady S.M., Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011, 186:4375-4387.
9. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181:4780-4790.
10. Suzukawa M., Iikura M., Koketsu R., Nagase H., Tamura C., Komiya A., et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008, 181:5981-5989.
11. Cherry W.B., Yoon J., Bartemes K.R., Iijima K., Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008, 121:1484-1490.
12. Allakhverdi Z., Smith D.E., Comeau M.R., Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007, 179:2051-2054.
13. Moro K., Yamada T., Tanabe M., Takeuchi T., Ikawa T., Kawamoto H., et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010, 463:540-544.
14. Neill D.R., Wong S.H., Bellosi A., Flynn R.J., Daly M., Langford T.K., et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464:1367-1370.
15. Brickshawana A., Shapiro V.S., Kita H., Pease L.R. Lineage-Sca1+c-Kit-CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol 2011, 187:5795-5804.
16. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
17. Chow J.Y., Wong C.K., Cheung P.F., Lam C.W. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010, 7:26-34.
18. Suzukawa M., Koketsu R., Iikura M., Nakae S., Matsumoto K., Nagase H., et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008, 88:1245-1253.
19. Na H.J., Hudson S.A., Bochner B.S. IL-33 enhances Siglec-8 mediated apoptosis of human eosinophils. Cytokine 2012, 57:169-174.
20. Kopf M., Brombacher F., Hodgkin P.D., Ramsay A.J., Milbourne E.A., Dai W.J., et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24.
21. Yu C., Cantor A.B., Yang H., Browne C., Wells R.A., Fujiwara Y., et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 2002, 195:1387-1395.
22. Dyer K.D., Garcia-Crespo K.E., Killoran K.E., Rosenberg H.F. Antigen profiles for the quantitative assessment of eosinophils in mouse tissues by flow cytometry. J Immunol Methods 2011, 369:91-97.
23. Ohto-Ozaki H., Kuroiwa K., Mato N., Matsuyama Y., Hayakawa M., Tamemoto H., et al. Characterization of ST2 transgenic mice with resistance to IL-33. Eur J Immunol 2010, 40:2632-2642.
24. Dyer K.D., Czapiga M., Foster B., Foster P.S., Kang E.M., Lappas C.M., et al. Eosinophils from lineage-ablated delta dblGATA bone marrow progenitors: the dblGATA enhancer in the promoter of GATA-1 is not essential for differentiation ex vivo. J Immunol 2007, 179:1693-1699.
25. Cavaillon J.M. Cytokines and macrophages. Biomed Pharmacother 1994, 48:445-453.
26. Menten P., Wuyts A., Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13:455-481.
27. Netea M.G., Demacker P.N., Kullberg B.J., Boerman O.C., Verschueren I., Stalenhoef A.F., et al. Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology 1998, 95:466-472.
28. Soehnlein O., Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010, 10:427-439.
29. Rosenberg H.F., Dyer K.D., Foster P.S. Eosinophils: changing perspectives in health and disease. Nature Reviews Immunology 2013, 13:9-22.
30. Ikutani M., Yanagibashi T., Ogasawara M., Tsuneyama K., Yamamoto S., Hattori Y., et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 2012, 188:703-713.
31. Stolarski B., Kurowska-Stolarska M., Kewin P., Xu D., Liew F.Y. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol 2010, 185:3472-3480.
32. Edling C.E., Hallberg B. c-Kit-a hematopoietic cell essential receptor tyrosine kinase. The International Journal of Biochemistry & Cell Biology 2007, 39:1995-1998.
33. Buza-Vidas N., Cheng M., Duarte S., Charoudeh H.N., Jacobsen S.E., Sitnicka E. FLT3 receptor and ligand are dispensable for maintenance and posttransplantation expansion of mouse hematopoietic stem cells. Blood 2009, 113:3453-3460.
34. Hudak S., Hunte B., Culpepper J., Menon S., Hannum C., Thompson-Snipes L., et al. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood 1995, 85:2747-2755.
35. Ishihara K., Satoh I., Mue S., Ohuchi K. Generation of rat eosinophils by recombinant rat interleukin-5 in vitro and in vivo. Biochim Biophys Acta 2000, 1501:25-32.
36. Schneider E., Petit-Bertron A.F., Bricard R., Levasseur M., Ramadan A., Girard J.P., et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 2009, 183:3591-3597.
37. Mayuzumi N., Matsushima H., Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009, 39:3331-3342.
38. Espinassous Q., Garcia-de-Paco E., Garcia-Verdugo I., Synguelakis M., von Aulock S., Sallenave J.M., et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009, 183:1446-1455.
39. Joshi A.D., Oak S.R., Hartigan A.J., Finn W.G., Kunkel S.L., Duffy K.E., et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol 2010, 11:52.
40. Kurowska-Stolarska M., Stolarski B., Kewin P., Murphy G., Corrigan C.J., Ying S., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009, 183:6469-6477.
41. Ohno T., Oboki K., Morita H., Kajiwara N., Arae K., Tanaka S., et al. Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS ONE 2011, 6:e18404.
42. Zaiss M.M., Kurowska-Stolarska M., Bohm C., Gary R., Scholtysek C., Stolarski B., et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol 2011, 186:6097-6105.
43. Barlow J.L., Bellosi A., Hardman C.S., Drynan L.F., Wong S.H., Cruickshank J.P., et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012, 129:191-198.